Purpose: To assess the binding of the PET tracer [18F]THK5351 in patients with different primary progressive aphasia (PPA) variants and its correlation with clinical deficits. The majority of patients with nonfluent variant (NFV) and logopenic variant (LV) PPA have underlying tauopathy of the frontotemporal lobar or Alzheimer disease type, respectively, while patients with the semantic variant (SV) have predominantly transactive response DNA binding protein 43-kDa pathology. Methods: The study included 20 PPA patients consecutively recruited through a memory clinic (12 NFV, 5 SV, 3 LV), and 20 healthy controls. All participants received an extensive neurolinguistic assessment, magnetic resonance imaging and amyloid biomarker tests. [18F]THK...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...
Primary progressive aphasia (PPA) is a neurodegenerative disorder causing prominent language impairm...
OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography...
Purpose To assess the binding of the PET tracer [18F]THK5351 in patients with different primary prog...
PURPOSE: In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic va...
Abstract Background Semantic variant primary progressive aphasia (svPPA) is a subtype of primary pro...
Introduction Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA...
We analyzed 18F-flortaucipir uptake patterns and structural changes in patients with subtypes of pri...
Despite epidemiological and genetic data linking semantic dementia to inflammation, the topography o...
Background: A subset of patients with the nonfluent variant of primary progressive aphasia (PPA) exh...
Objective: Alzheimer’s disease (AD) is found at autopsy in up to one third of patients with primary ...
The use of biomarkers has recently supported the association between Alzheimer’s disease (AD) pathol...
ObjectiveTo characterize in vivo signatures of pathological diagnosis in a large cohort of patients ...
Importance:The ability to predict the pathology underlying different neurodegenerative syndromes is ...
Background: Primary progressive aphasia (PPA) is associated with amyloid-β (Aβ) pathology. However, ...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...
Primary progressive aphasia (PPA) is a neurodegenerative disorder causing prominent language impairm...
OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography...
Purpose To assess the binding of the PET tracer [18F]THK5351 in patients with different primary prog...
PURPOSE: In vivo tau-PET tracer retention in the anterior temporal lobe of patients with semantic va...
Abstract Background Semantic variant primary progressive aphasia (svPPA) is a subtype of primary pro...
Introduction Semantic dementia, including the semantic variant of primary progressive aphasia (svPPA...
We analyzed 18F-flortaucipir uptake patterns and structural changes in patients with subtypes of pri...
Despite epidemiological and genetic data linking semantic dementia to inflammation, the topography o...
Background: A subset of patients with the nonfluent variant of primary progressive aphasia (PPA) exh...
Objective: Alzheimer’s disease (AD) is found at autopsy in up to one third of patients with primary ...
The use of biomarkers has recently supported the association between Alzheimer’s disease (AD) pathol...
ObjectiveTo characterize in vivo signatures of pathological diagnosis in a large cohort of patients ...
Importance:The ability to predict the pathology underlying different neurodegenerative syndromes is ...
Background: Primary progressive aphasia (PPA) is associated with amyloid-β (Aβ) pathology. However, ...
OBJECTIVE: To estimate the prevalence of amyloid-positivity, defined by PET/CSF biomarkers and/or ne...
Primary progressive aphasia (PPA) is a neurodegenerative disorder causing prominent language impairm...
OBJECTIVE: To estimate the prevalence of amyloid positivity, defined by positron emission tomography...